Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India and internationally. The company offers formulations for anti-infectives, pain and analgesics, respiratory, gastroenterology, gynecology, rheumatology, and central nervous system, as well as for vitamins, minerals, and nutrition. It also provides API products for antidiabetics, antihistamines, antitussives, analgesics, antidepressants, and anti-inflammatory medicines. The company was formerly known as Pearl Organics Limited and changed its name to Wanbury Limited in 2004. Wanbury Limited was incorporated in 1988 and is headquartered in Navi Mumbai, India.
| Current Price | ₹258.30 |
|---|---|
| Market Cap | ₹901 Cr |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Pharmaceutical Products |
| P/E Ratio | 13.3 |
| Return on Equity | 64.93% |
| 52-Week Range | ₹161.50 – ₹320.95 |
| Beta (1Y) | 0.43 |
| Dividend Yield | 0.00% |
Wanbury Ltd. is trading at ₹258.30, with a market capitalisation of ₹901 Cr.
Wanbury Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Pharmaceutical Products).
Wanbury Ltd. has a P/E of 13.3 and a return on equity of 64.93%.